# Dossier: NUSHORES BIOSCIENCES LLC

## SBIR Award Details

**Award Title:** N/A

**Amount:** $3,000,000.00

**Award Date:** 2024-09-18

**Branch:** DHA

## AI-Generated Intelligence Summary

**Company Overview:**

Nushores Biosciences LLC is a biotech company focused on developing and commercializing a rapid, point-of-care diagnostic platform based on their proprietary peptide-targeted biosensors for the detection of biological threats and medical conditions. Their core mission appears to be centered around improving biosurveillance and medical diagnostics, particularly in situations requiring quick and accurate results in resource-constrained environments. The company aims to solve the problem of slow, lab-based diagnostics that limit the speed of response to outbreaks, potential bioterrorism events, and critical care scenarios. Nushores' unique value proposition lies in its ability to deliver high-sensitivity, high-specificity diagnostic tests with a quick turnaround time, potentially without the need for complex laboratory infrastructure.

**Technology Focus:**

* Proprietary peptide-targeted biosensors: These biosensors are designed to selectively bind to specific target analytes, such as toxins, pathogens, or disease biomarkers, enabling rapid and accurate detection.
* Point-of-care diagnostic platform: The platform allows for on-site testing, eliminating the need to send samples to a centralized lab and significantly reducing the time to result. The platform appears designed to be portable and usable by individuals with limited technical training.

**Recent Developments & Traction:**

* In July 2021, Nushores Biosciences announced a cooperative research and development agreement (CRADA) with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate their technology for rapid detection of viral pathogens.
* In May 2023, Nushores Biosciences received a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) for the development of a portable diagnostic device for the detection of antibiotic-resistant bacteria.

**Leadership & Team:**

The information available is limited. Public sources do not provide detailed biographies or specific roles of the leadership team beyond the company name being associated with scientific publications and patent applications. Further investigation is required to assess the depth of experience within the team.

**Competitive Landscape:**

1. Senseonics: While focusing more on continuous glucose monitoring, Senseonics' implanted sensor technology demonstrates capabilities in long-term, in-vivo analyte detection. Nushores differentiates itself through its focus on broad-spectrum pathogen detection and point-of-care applications.

2. Numerous companies developing rapid diagnostic tests for specific pathogens (e.g., COVID-19 tests). Nushores aims to differentiate through the development of a flexible platform technology adaptable to various targets, offering a broader diagnostic capability than single-target tests.

**Sources:**

1. [https://www.usamriid.army.mil/index.cfm/newsroom/articles/article/3211542/usamriid-collaborates-with-nushores-biosciences-on-detection-of-viral-pathoge](https://www.usamriid.army.mil/index.cfm/newsroom/articles/article/3211542/usamriid-collaborates-with-nushores-biosciences-on-detection-of-viral-pathoge)

2. [https://www.nsf.gov/awardsearch/showAward?AWD\_ID=2223001](https://www.nsf.gov/awardsearch/showAward?AWD\_ID=2223001)

3. [https://patents.google.com/patent/US11415596B2/en](https://patents.google.com/patent/US11415596B2/en)